2 completed, 1 recruiting, 1 terminated. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Recruiting 1, Terminated 1 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
Follow lanreotide: new trials by email Literature Review of lanreotide trials Research Report on lanreotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Debio 4126, Sandostatin LAR, Somatuline ATG - Acromegaly, GEP-NET | Phase 1 | Terminated | Debiopharm International SA | 19 | 2022-05-18 | 2025-11-17 |
| Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors Cabozantinib, Lanreotide - Neuroendocrine Tumors,Gastroenteropancreatic | Phase 1 / Phase 2 | Recruiting | National Health Research Institutes, Taiwan | 49 | 2021-09-17 | 2026-04-09 |
| Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors Lanreotide, Pembrolizumab - Gastroenteropancreatic Neuroendocrine Tumors | Phase 1 / Phase 2 | Completed | Duke University | 22 | 2017-07-01 | 2023-06-29 |
| Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly Lanreotide PRF - Acromegaly | Phase 1 / Phase 2 | Completed | Ipsen | 28 | 2015-03-01 | 2019-04-25 |
Acromegaly (2) · Gastro-enteropancreatic neuroendocrine tumor (2) · Neuroendocrine Tumors (1)
Debiopharm International SA (1) · Duke University (1) · Ipsen (1) · National Health Research Institutes, Taiwan (1)
France (2) · Germany (2) · Italy (2) · Poland (2) · Spain (2) · United Kingdom (2) · Belgium (1) · Czechia (1) · Denmark (1) · Israel (1) · Lithuania (1) · Netherlands (1) · Romania (1) · Russia (1) · Taiwan (1)
Hui-Jen Tsai, PhD (1) · Michael Morse, MD (1)
2014 (1)